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Abstract
Background: BRCA2 germ-line mutations predispose to breast and ovarian cancer. Mutations are
widespread and unclassified splice variants are frequently encountered. We describe the parental
origin and functional characterization of a novel de novo BRCA2 splice site mutation found in a
patient exhibiting a ductal carcinoma at the age of 40.
Methods:  Variations were identified by denaturing high performance liquid chromatography
(dHPLC) and sequencing of the BRCA1 and BRCA2 genes. The effect of the mutation on splicing was
examined by exon trapping in COS-7 cells and by RT-PCR on RNA isolated from whole blood. The
paternity was determined by single nucleotide polymorphism (SNP) microarray analysis. Parental
origin of the de novo mutation was determined by establishing mutation-SNP haplotypes by variant
specific PCR, while de novo and mosaic status was investigated by sequencing of DNA from
leucocytes and carcinoma tissue.
Results: A novel BRCA2 variant in the splice donor site of exon 21 (nucleotide 8982+1 G→A/
c.8754+1 G→A) was identified. Exon trapping showed that the mutation activates a cryptic splice
site 46 base pairs 3' of exon 21, resulting in the inclusion of a premature stop codon and synthesis
of a truncated BRCA2 protein. The aberrant splicing was verified by RT-PCR analysis on RNA
isolated from whole blood of the affected patient. The mutation was not found in any of the
patient's parents or in the mother's carcinoma, showing it is a de novo mutation. Variant specific
PCR indicates that the mutation arose in the male germ-line.
Conclusion: We conclude that the novel BRCA2 splice variant is a de novo mutation introduced in
the male spermatozoa that can be classified as a disease causing mutation.
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Background
Germ-line BRCA2 (MIM# 600185) mutations in female
carriers confer a lifetime risk exceeding 80% for breast
cancer and 20% for ovarian cancer, and a moderate
increased risk of other cancer types [1,2]. Studies have
indicated that the risk of ovarian cancer is greatest in
women with BRCA2 mutations localized in nucleotides
3035–6629 [3,4]. Several genes are likely to be involved in
breast cancer predisposition, but no susceptibility gene
aside BRCA2 and BRCA1 is likely to account for a large
fraction or a major increase in risk [5].
The BRCA2 gene spans approximately 70 kb and is com-
posed of 27 exons, which encodes a protein of 3418
amino acids. BRCA2 is involved in homologous recombi-
nation [6,7], but is also suggested to play a role in tran-
scriptional regulation [8] and cell cycle control [9].
Mutations are distributed throughout the entire coding
region of BRCA2 and to date numerous deleterious muta-
tions have been reported (Breast Cancer Information Core
[BIC]; [10]). The majority of patients with BRCA1  or
BRCA2  associated breast and/or ovarian cancer have a
family history, although healthy male carriers may
obscure the apparent dominant trait. Several BRCA2
founder mutations have been identified, including the
Ashkenazi Jewish nucleotide 6174delT mutation and the
Icelandic nucleotide 999del5 mutation [11,12]. In con-
trast, only two mutations in BRCA2 and one in BRCA1
have been reported as de novo mutations [13-15], but since
a positive family history is one of the criteria for mutation
screening, it is possible that we overlook a number of
patients with these mutations.
Here we report the functional characterization of a novel
de novo BRCA2 splice site mutation located in the inter-
vening sequence (IVS) of exon 21 (nucleotide 8982+1
G→A/c.8754+1 G→A) in a Danish breast cancer patient
with a family history of breast cancer. The parental origin
of the mutation is assigned to the father.
Methods
Patients
Family B49363 is a 23 member, three-generation kindred
with two affected subjects. A 40 year old woman was
referred to genetic counseling two months after she had
breast-conserving surgery at Roskilde County Hospital
with radical excision of an 8 mm large invasive ductal car-
cinoma. The tumor was estrogen and progesterone recep-
tor positive and had malignancy grade II. The patient
received adjuvant radiotherapy followed by seven series of
chemotherapy with CEF and tamoxifen. The patient's
mother had a mastectomy at age 59 with excision of a 22
mm large estrogen and progesterone receptor positive
invasive ductal carcinoma, malignancy grade II, and post-
operatively she received tamoxifen. Following verbal and
written consent, blood and tumour samples were col-
lected from the proband for mutation screening and after
renewed consent a third blood sample was collected for
RNA analysis. Moreover, blood and tumour samples from
the patient's mother, and blood samples from the
patient's father and sister were collected. The family his-
tory was verified using the registry of the DBCG (Danish
Breast Cancer Cooperative Group), hospital medical
records and pathology reports, and genetic counselling
was provided for each family member. Since the study is
part of normal diagnostic procedures no ethical approval
was obtained. The study was conducted in accordance
with the Helsinki Declaration.
BRCA1 and BRCA2 screening
Genomic DNA was purified from whole blood using the
QIAamp DNA mini kit (Qiagen) according to the manu-
facturer's instructions. BRCA1 and BRCA2 were amplified
using intronic primer pairs flanking each exon. PCR prod-
ucts were pre-screened by dHPLC (denaturing high per-
formance liquid chromatography) using the WAWE
system (Transgenomic) and sequenced using an ABI3730
DNA analyzer (Applied Biosystems). Sequence variations
were verified in a new blood sample. Moreover genomic
DNA was examined by MLPA analysis (MRC-Holland).
The BRCA1 variant is numbered according to GenBank
accession number U14680, in which the A in the AUG
start codon has number 120, whereas the BRCA2 variant
is numbered according to GenBank accession number
NC_000059, in which A in the AUG start codon has
number 229. Moreover, the BRCA1 and BRCA2 variants
are numbered according to GenBank accession number
NC_000017.9 and NC_000013.9 using the guidelines
from the Human Genetic Variation Society [16].
Vector constructs
The pSPL3 vector was obtained from Gibco-BRL. pSPL3-
BRCA2-wild-type and pSPL3-BRCA2-mutant plasmids,
containing BRCA2 exon 21 and flanking intron
sequences, were constructed by PCR using purified DNA
from human blood samples and the following oligonu-
cleotides: BRCA2-F, 5'-GATCACGAATTCTTCCT-
GGAAAACTTATAGCA-3' and BRCA2-R 5'-
GATCACCTCGAGTTAGGGTAGAGGATTATCAAGTACA-
3'. The PCR products were treated with EcoRI and XhoI
and cloned into the pSPL3 vector. All constructs were ver-
ified by sequencing.
Cell culture and transfections
COS-7 cells were cultured in Dulbecco's modified Eagle's
medium (DMEM) containing 4500 mg/l glucose supple-
mented with 10% foetal bovine serum, 100 U of penicil-
lin per ml, and 100 μg of streptomycin per ml at 5% CO2
and 37°C. One day before transfection, cells were seeded
in 6-well culture dishes at a density of 4 × 105 cells/well.BMC Medical Genetics 2008, 9:58 http://www.biomedcentral.com/1471-2350/9/58
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Cells were transfected with a total of 4 μg plasmid DNA
using FuGENE 6 transfection reagent (Roche) according
to the manufacturer's instructions. Transfection efficien-
cies for each series were determined by cotransfection of
pEGFP plasmid (Clontech). The next day the media was
changed and after another 24 h the cells were harvested
and total RNA was isolated using Trizol reagent (Invitro-
gen).
Exon trapping analysis
First strand cDNA was synthesized using 1 μg RNA, 20 μM
SA2 primer (5'-ATCTCAGTGGTATTTGTGAGC-3') and M-
MuLV reverse transcriptase (New England Biolabs). The
cDNAs were amplified with pSPL3 vector-specific primers
(5'-TCTGAGTCACCTGGACAACC-3' and 5'-ATCTCAGT-
GGTATTTGTGAGC-3') and the PCR products were
resolved on a 2% agarose gel. All experiments were
repeated three times.
RNA analysis
A fresh blood sample was obtained from the patient. Total
cellular RNA was isolated with Trizol (Invitrogen) accord-
ing to the manufacturer's instructions. For reverse tran-
scription-PCR (RT-PCR), cDNA was synthesized using the
AMV reverse transcriptase (Promega) as described by the
supplier. The cDNA were amplified with the BRCA2 spe-
cific primers 5'-CGGCCTGCTCGCTGGTAT-3' and 5'-
GCCTTCCTAATTTCCAACTGGATCTG-3' resulting in a
503 bp fragment. The samples were separated by agarose
gel electrophoresis and visualized by ethidium bromide
staining. Finally, the bands were purified, cloned into
pCR-Blunt II-TOPO (Invitrogen) and sequenced using an
ABI3730 DNA analyzer (Applied Biosystems).
SNP chip analysis
Genomic DNA was applied to 250K StyI (~238.000 SNPs)
SNP-microarray chips and processed according to the
manufacturer's instructions (Affymetrix, UK). Briefly, 250
ng of genomic DNA was digested with StyI and ligated to
adapters. Adapter-ligated DNA was amplified, purified,
fragmented and labeled with biotin and hybridized to the
arrays for 18 h. The Affymetrix 450 fluidics station and the
Affymetrix 3000 G7 gene scanner were used to wash,
stain, and scan the arrays. The CEL files were analysed
using the BRLMM algorithm from Affymetrix Genotyping
analysis software (GTYPE). Relationship was inferred by
estimating the pairwise identical by descent (IBD) shar-
ing, as described [17].
Assignment of parental origin
Variant specific primers were designed using the software
Primer3 in combination with ClustaIW alignments. The
primer sets distinguish the wild-type allele (BRCA2
c.8754+1-G forward: 5'-AGACCCAGCTTACCTTGACG-
3') from the mutation carrying allele (BRCA2 c.8754+1-A
forward: 5'-CAGACCCAGCTTACCTTGAAA-3'), and the
two SNP alleles in rs4942485 (rs4942485*A reverse: 5'-
CTACATTACAGATGGCTAATATCTGATT-3' and
rs4942485*G reverse: 5'-CATTACAGATGGCTAATATCT-
GAAC-3'. Primer sets were tested on homozygote controls
and unspecific annealing was avoided after introducing
mismatches (marked in bold). PCR was carried out using
standard conditions according to the manufacturer's pro-
tocols using the Expand High FidelityPLUS  Taq DNA
polymerase (Roche). Allele sizes were: BRCA2 c.8754+1-G
and rs942485-G = 2297 bp, BRCA2  c.8754+1-*A and
rs942485-G = 2298 bp, BRCA2  c.8754+1-G and
rs942485-A = 2300 bp, BRCA2  c.8754+1-*A and
rs942485-A = 2301 bp.
Results and discussion
The patient was diagnosed with breast cancer at the age of
40. Since her mother had breast cancer at the age of 59
(Fig. 1), the patient was referred to genetic counselling.
No other family members had breast or ovarian cancer.
We analysed the entire coding region and the exon-intron
boundaries of BRCA1 and BRCA2 from genomic DNA by
dHPLC and sequencing and for large genomic rearrange-
ments by MLPA analysis. The analysis revealed a polymor-
phism in exon 11 of BRCA1  (nucleotide 1186 A→G/
c.1067 A→G), which is observed in approximately 5% of
a control group [18], and a nucleotide 8982+1 G→A/
c.8754+1 G→A mutation in BRCA2 that has not previ-
ously been reported in the BIC database (Fig. 2). The
mutation occurs at the first base of the conserved GU
splice donor site of intron 21. The mutation was verified
in a second blood sample as well as in breast cancer
tumour tissue.
To functionally characterize the BRCA2  nucleotide
8982+1 G→A/c.8754+1 G→A variant, a fragment con-
taining BRCA2 exon 21 (122 bp), 449 bp of intron 20
(IVS20) and 408 bp of intron 21 (IVS21) containing the
wild-type or the nucleotide 8982+1 G→A/c.8754+1 G→A
variant, respectively, was cloned into the minigene vector
pSPL3 containing exons from HIV-tat under the control of
the SV40 promoter (Fig. 3A) [19]. Constructs containing
either the wild-type or the mutant IVS21 sequence was
transfected into COS-7 cells. After 48 hours mRNA was
purified and examined by RT-PCR. The splicing products
were separated on a 2% agarose gel. The wild-type con-
struct yields a product of 299 bp and a product of 177 bp
if exon 21 is excluded from the transcript (exon skipping).
Moreover a larger product than 299 bp would demon-
strate that additional intron sequence is included in the
transcript. The normal wild-type BRCA2 exon 21 (pSPL3-
BRCA2-wt) generated one transcript comprising the
expected 299 bp, while the BRCA2  nucleotide 8982+1
G→A/c.8754+1 G→A mutant (pSPL3-BRCA2-mut)
yielded a band with slightly higher mobility (Fig. 3B).BMC Medical Genetics 2008, 9:58 http://www.biomedcentral.com/1471-2350/9/58
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Sequencing revealed, that it contained an additional 46
bp from intron 21 generating a transcript of 345 bp (Fig.
3C), indicating that it activates a cryptic splice site follow-
ing these 46 bp (Fig. 1). To provide direct evidence for the
aberrant splicing, RNA was isolated from whole blood of
the affected patient and RT-PCR was performed before the
products were analysed on a 1% agarose gel (Fig. 4). Two
PCR products – one with the expected size of the wild-
type (503 bp) and an additional RT-PCR product (549
bp) – were amplified from the patient. Cloning and
sequence analysis of the latter verified the inclusion of 46
bp of intron 21 (data not shown).
We examined the patient's mother, who was affected with
the same type of breast cancer at the age of 59 years, for
the same mutation, but she did not have this mutation in
either DNA purified from blood or breast cancer tumour
samples. Therefore mosaicism was excluded. Moreover,
the father and the patient's sister did not carry the muta-
tion. To establish the paternity we performed a SNP
microarray analysis using 250K Sty gene array (Affyme-
trix). The analysis provided the relatedness estimates
(Table 1), where k0 is the probability that pairs of individ-
uals at a random loci share no allele identical by descent
(IBD), k1 is the probability that pairs of individuals at a
random loci share one allele IBD, and k2 the probability
that pairs of individuals at a random loci share two allele
IBD. The expected relatedness for full siblings is k0 = 0.25,
k1 = 0.5, k2 = 0.25, for parent offspring k0 = 0, k1 = 1, k2
= 0, for unrelated k0 = 1, k1 = 0, k2 = 0, which in all cases
fits in this family. We therefore conclude that the identi-
fied mutation in the proband is a de novo mutation in
BRCA2. In contrast to the previously identified de novo
BRCA2  nucleotide 3034del4 and BRCA1  nucleotide
3888delGA mutations [14,15], the mutation reported in
our study resides in a new position not previously
reported in the BIC database. This was also the case with
the BRCA2 nucleotide 7260insA mutation [13]. Several
other variants have been detected in the vicinity of the
splice donor site in exon 21, including nucleotide 8982
G→A/c.8754 G→A (reported once), nucleotide 8982+1
A→G/c.8754+4 A→G (reported seven times), nucleotide
Family pedigree Figure 1
Family pedigree. Breast cancers are indicated as well as 
the age at diagnosis. Acc, accident; BRC, breast cancer. The 
number following the cancer gives the age at diagnosis. 
Moreover, the genotypes from variant specific PCR are indi-
cated. Diagonal slash indicates deceased. The proband is indi-
cated with an arrow. Proband = individual 1, Sister = 
individual 2, Mother = individual 3, Father = individual 4.
BRC 59 
Acc. 49 yrs
BRCA2 c.8754+1 A*  G
r s4942485 G   A  
G   G
G   A
BRC 40
BRCA2 c.8754+1 G   G
rs4942485 G   G
G   G
A    A
43
12
Identification of the BRCA2 nucleotide 8982+1 G→A/c Figure 2
Identification of the BRCA2 nucleotide 8982+1 G→A/c.8754+1 G→A variant. DNA was purified from whole blood 
and BRCA2 exon 21 was amplified using the primers 5'-CTTTGGGTGTTTTATGCTTGT-3' and 5'-CTGGCACATCACT-
GAAAATC-3' and sequenced. The analysis revealed a nucleotide 8982+1 G→A/c.8754+1 G→A mutation in BRCA2 (sense 
strand). The nucleotide 8982+1 G→A/c.8754+1 G→A mutation and the cryptic splice site are underlined.
Exon 21 Intron 21
G>ABMC Medical Genetics 2008, 9:58 http://www.biomedcentral.com/1471-2350/9/58
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Exon trapping analysis Figure 3
Exon trapping analysis. (A) Structure of the exon trapping vector pSPL3 containing the BRCA2 exon 21 and 449 bp of 
intron 20 and 408 bp of intron 21, respectively containing the wild-type or the nucleotide 8982+1 G→A/c.8754+1 G→A vari-
ant. (B) COS-7 cells were transfected with pSPL3-BRCA2-exon 21 wild-type or pSPL3-BRCA2-exon 21 mutant plasmids. Total 
RNA was isolated, RT-PCR analysis was performed and the PCR products (in duplicates) were resolved on a 2% agarose gel. 
The 299 bp product corresponds to wild-type exon 21 (unaltered splicing), while the 345 bp product corresponds to exon 21 
and the inclusion of 46 bp of intron 21. The sizes of the DNA marker are indicated to the right. (C) Sequence of exon 21 (345 
bp band). The nucleotide 8982+1 G→A/c.8754+1 G→A mutation and the TAA stop codon are underlined (sense strand).
 
BRCA2 exon 21 pSPL3 pSPL3
122 bp
IVS20 IVS21 SD SA
449 bp 408 bp
A 
B 
C 
Exon 21 Intron 21 pSPL3
Exon 21
wild-type
Exon 21
 mutant
200 bp
500 bp
766 bp
299 bp
345 bp
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8982+5 G→A/c.8754+5 G→A (reported once) and nucle-
otide 8982+5 G→T/c.8754+5 G→T (reported once), sug-
gesting that this region could be prone to mutations.
To determine the parental origin of the mutation, variant
specific PCR was performed using primers designed to dis-
tinguish between two SNP alleles and the mutation carry-
ing allele from the wild-type allele. The father was
homozygote for the haplotype GG, while the mother was
homozygote for the haplotype GA (see Fig. 1). PCR anal-
ysis of the proband revealed a band using mutant BRCA2
and rs4942485*G primers, indicating that the haplotype
*AG must derive from the father, and that the mutation
therefore arose in the testicular germ cells changing
BRCA2 nucleotide 8982+1/c.8754+1 from G to A. This is
in agreement with previous findings in BRCA1  [14],
whereas the studies describing de novo mutations in
BRCA2 were unable to determine parental origin [13,15].
Examinations of other cancer families, including MEN2B
and retinoblastoma families have indicated that de novo
mutations primarily occur in the male germ line [20,21]
and that the fathers age is a major determinant since
mutations accumulate during life [22]. It is, however,
noteworthy that the age of the probands parents in our
study was only 19 and 21 years at the time of birth of their
affected daughter.
Conclusion
We conclude that the BRCA2 nucleotide 8982+1 G→A/
c.8754+1 G→A mutation is a de novo mutation arising
from the male germ line. The mutation is not previously
reported in the BIC database. It leads to the activation of
a cryptic splice site 46 base pairs 3' of exon 21 and intro-
duces a premature stop codon and thereby a truncated
BRCA2 protein. Therefore, this mutation can be classified
as a disease-causing mutation. Analysis of intronic BRCA1
and BRCA2 variants by functional splicing assays can pro-
vide information that can be used clinically.
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